pharma · Obesity · Type 2 diabetes
NovoThirteen
NovoThirteen is a pharma organization headquartered in Bagsværd, JP. Primary therapeutic focus areas include Obesity, Type 2 diabetes, Type 2 Diabetes, Mild cognitive impairment (MCI) or mild dementia, both of the Alzhei
Bagsværd, JP HQ
PMDA registrant Type
Company details
- Status
- Public
- HQ
- Bagsværd, JP
- Programs
- 94
- Drugs
- 67
- Patents
- 0
NN6706-8282
Phase 2 · other · Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy.
NN6706-8282 for Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy. is a Phase 2 program (other) at NovoThirteen with 1 ClinicalTrials.gov record(s).
Internal code NN6706-8282
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- NovoThirteen
- Phase
- Phase 2
- Modality
- other
- Indication
- Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy.
- Status
- active
- Trials
- 1